SpectrumX said recent changes to its state-of-the-art production facility in Knutsford, Cheshire, have paved the way towards the production of drug substance, SPC-069, for clinical trials.
Upgrades included an ISO Class 8 Cleanroom, which includes a best-in-class air purification, ventilation, and pressure-cascade system to prevent air contaminants during manufacturing processes.
A dedicated quality control room and a microbiology laboratory, which tests all raw materials, key manufacturing steps and finished cosmetic and biocide products have also been added.
SpectrumX said it now has the base to start preparations for a clinical trial programme to take its novel respiratory treatment, SPX-001, to market.
Ben Hibbert, SpectrumX’s operations director, said: “We are delighted our Knutsford facility now meets the standards required for the production of a pharmaceutical drug substance - in our case, SPC-069.
“To achieve this, we installed equipment across the facility and introduced new operating procedures.
“This is a significant step for the business as it allows us to kickstart our clinical trial programme.
“We now have the right environment to create and distribute our full range of hypochlorous acid products, which we believe will be game-changers in the market.”